Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of “Hold” by Brokerages

Coherus Oncology, Inc. (NASDAQ:CHRS) has been assigned a consensus recommendation of “Hold” from the five brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $4.5125.

CHRS has been the subject of several analyst reports. Wall Street Zen upgraded Coherus Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Maxim Group raised Coherus Oncology from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research note on Thursday, September 4th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Coherus Oncology in a research note on Wednesday, October 8th.

Coherus Oncology Price Performance

Shares of NASDAQ:CHRS opened at $1.31 on Friday. The company has a current ratio of 1.24, a quick ratio of 1.23 and a debt-to-equity ratio of 0.42. The stock’s fifty day simple moving average is $1.54 and its two-hundred day simple moving average is $1.15. Coherus Oncology has a 1-year low of $0.71 and a 1-year high of $2.43. The stock has a market cap of $158.34 million, a PE ratio of 0.98 and a beta of 0.96.

Coherus Oncology (NASDAQ:CHRS) last announced its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The business had revenue of $11.57 million during the quarter, compared to the consensus estimate of $13.41 million. As a group, analysts forecast that Coherus Oncology will post -1.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Coherus Oncology

Institutional investors and hedge funds have recently modified their holdings of the stock. Quarry LP bought a new stake in shares of Coherus Oncology in the 3rd quarter worth approximately $26,000. Focus Partners Wealth purchased a new position in shares of Coherus Oncology during the third quarter valued at approximately $70,000. Two Sigma Investments LP bought a new position in shares of Coherus Oncology during the 3rd quarter valued at $59,000. Bridgeway Capital Management LLC boosted its position in Coherus Oncology by 78.3% in the third quarter. Bridgeway Capital Management LLC now owns 255,000 shares of the biotechnology company’s stock worth $418,000 after purchasing an additional 112,000 shares during the last quarter. Finally, UBS Group AG grew its position in Coherus Oncology by 38.5% during the third quarter. UBS Group AG now owns 795,941 shares of the biotechnology company’s stock valued at $1,305,000 after buying an additional 221,410 shares during the period. 72.82% of the stock is owned by hedge funds and other institutional investors.

Coherus Oncology Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.